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Pre-Treatment of Mesenchymal Stem Cells With
a Combination of Growth Factors Enhances Gap Junction
Formation, Cytoprotective Effect on Cardiomyocytes,
and Therapeutic Efficacy for Myocardial Infarction
Joo-Yong Hahn, MD, PHD,*† Hyun-Ju Cho, MS,* Hyun-Jae Kang, MD, PHD,*†
Tack-Seung Kim, MS,‡ Mi-Hyung Kim, PHD,‡ Jung-Hwa Chung, MD,* Jang-Whan Bae, MD, PHD,*
Byung-Hee Oh, MD, PHD,*† Young-Bae Park, MD, PHD,*† Hyo-Soo Kim, MD, PHD*†
Seoul, Republic of Korea
Objectives The goal of this study was to investigate the effect of pre-treatment of mesenchymal stem cells (MSCs) with
growth factors (GFs) on cardiomyogenic differentiation, cytoprotective action on cardiomyocytes (CMCs), and
their therapeutic efficacy in myocardial infarction.
Background Mechanisms of myocardial repair with MSC transplantation have not been fully elucidated, and therapeutic effi-
cacy needs to be enhanced.
Methods The MSCs obtained from the bone marrow of Fisher344 rats were treated with fibroblast growth factor-2, insulin-
like growth factor-1, and bone morphogenetic protein-2. The expression of cardiac specific markers and the cyto-
protective effect of MSCs with its mechanism were evaluated. Efficacy of MSCs transplantation was studied in
rat myocardial infarction model.
Results Treatment of MSCs with cocktails of GFs enhanced expression of cardiac transcription factors and survival. In-
duction of cardiac specific markers by coculture with CMCs and gap junctional communication with CMCs was
more active in GF-treated MSCs than untreated MSCs. The GF-treated MSCs reduced apoptosis of neighboring
CMCs in a hypoxic condition and enhanced the phosphorylated Akt and phosphorylated c-AMP response element
binding protein expression of CMCs, which was markedly reduced by gap junction blockade. In a rat myocardial
infarction model, transplantation of GF-treated MSCs resulted in smaller infarct size and better cardiac function than
transplantation of untreated MSCs. Additionally, GF treatment enhanced gap junction formation of transplanted MSCs,
which did not aggravate arrhythmia.
Conclusions Pre-treatment of MSCs with GFs enhanced cytoprotective effects on neighboring CMCs through gap junction and
improved the therapeutic efficacy of MSC transplantation for myocardial repair. “Priming of MSCs with GFs” be-
fore transplantation might improve the therapeutic efficacy of cell therapy. (J Am Coll Cardiol 2008;51:
933–43) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.040s
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sesenchymal stem cells (MSCs) have been reported to
epair damaged myocardium and improve cardiac function
fter myocardial infarction (MI) in pre-clinical studies (1,2).
one marrow cells containing MSCs were most widely
rom the *National Research Laboratory for Cardiovascular Stem Cells, Seoul
ational University College of Medicine, Seoul, Republic of Korea; †Innovative
esearch Institute for Cell Therapy, Seoul National University Hospital, Seoul,
epublic of Korea; and ‡Anterogen Corp., Seoul, Republic of Korea. This study was
upported by a grant from Stem Cell Research Center (SC3150) and from Innovative
esearch Institute for Cell Therapy, Republic of Korea. Drs. Hahn and Cho
ontributed equally to this work.i
Manuscript received August 20, 2007; revised manuscript received October 26,
007, accepted November 27, 2007.tudied in clinical trials; however, their therapeutic benefit
eeds to be improved (3,4). Although the underlying
echanisms have not been fully elucidated, the differenti-
tion of MSCs into cardiomyocytes (CMCs) might explain,
t least partly, their therapeutic effect. Additionally, MSCs
an exert cytoprotective effects on CMCs in a paracrine way.
substantial portion of the salutary effects of MSC im-
lantation might be attributable to salvage of endangered
schemic myocardium (5). Although MSCs secrete large
mounts of angiogenic and anti-apoptotic factors (6), the
echanisms of these cytoprotective effects are not fully under-
tood. Gap junctions allow exchange of small molecules,
ncluding secondary messengers between adjacent cells (7), and
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MSCs to exert cytoprotective
effects.
To improve efficacy of MSC
transplantation, interventions that
facilitate differentiation and en-
hance the cytoprotective effects
of MSC can be a rational ap-
proach. Recently, the role of
growth factors (GFs) in the dif-
ferentiation of stem cells into
CMCs has been studied, in-
cluding fibroblast growth factor
(FGF)-2, insulin-like growth fac-
tor (IGF)-1, and bone morphoge-
netic protein (BMP)-2 (8–11).
Combination of these GFs might
facilitate differentiation of MSCs
into CMCs. Furthermore, many
GFs stimulate an anti-apoptotic
signal, and FGF-2 and IGF-1
have been reported to increase the
expression of connexin-43 (12,13).
Pre-treatment of MSCs with GFs
might enhance transfer of anti-
apoptotic signal to CMCs.
In this study, we investigated
whether treatment of MSCs with
a combination of GFs (FGF-2,
IGF-1, and BMP-2) enhances
cardiomyogenic differentiation
and the cytoprotective effect of
MSCs, elucidating the potential
ole of gap junction in cytoprotective action of MSCs.
urthermore, to confirm the therapeutic applicability of
F-primed MSCs, we examined therapeutic efficacy of
F-treated MSCs in improving myocardial repair after
ransplantation in a rat MI model.
ethods
nimal care. All animal experiments were performed under
pproval from the Institutional Animal Care and Use Com-
ittee of Seoul National University Hospital and complied
ith the National Research Council’s “Guidelines for the Care
nd Use of Laboratory Animals” (revised 1996).
solation and culture of MSCs from rat bone mar-
ow. The MSCs were isolated from the femur of 8-week-
ld male Fischer 344 rats (200 to approximately 250 g,
aehan Biolink Co., Chungbuk, Korea). Bone marrow
lugs were extracted and suspended in MSC culture me-
ium (Dulbecco’s Modified Eagle Medium [DMEM, In-
itrogen, Carlsbad, California], 10% fetal bovine serum
FBS, Hyclone, Logan, Utah], ascorbic acid [Sigma, St.
Abbreviations
and Acronyms
BMP  bone
morphogenetic protein
CMC  cardiomyocyte
DMEM  Dulbecco’s
Modified Eagle Medium
FACS  fluorescence-
activated cell sorter
FBS  fetal bovine serum
FGF  fibroblast growth
factor
FS  fractional shortening
GF  growth factor
IGF  insulin-like growth
factor
LV  left
ventricle/ventricular
LVEDD  left ventricular
end-diastolic dimension
LVESD  left ventricular
end-systolic dimension
MEF  myocyte enhancer
factor
MI  myocardial infarction
MSC  mesenchymal stem
cell
RT-PCR  reverse
transcriptase-polymerase
chain reaction
VF  ventricular fibrillationouis, Missouri], dexamethasone [Sigma], and mouse leu- pemia inhibitory factor [Sigma]) and then incubated at
7°C for 3 days before the first medium change. The
esenchymal population was isolated on the basis of its
bility to adhere to the culture plate (14). At 90% conflu-
nce, the cells were trypsinized and subcultured. Second
assage MSCs were used in all experiments. The MSCs
ere labeled with vibrant 1.1=-dioctadecyl-3,3,3=,3=-
etramethylindocarbocyanine perchlorate (DiI, Molecular
robes, Eugene, Oregon) or with 4=,6-diamino-2-
henylindole (DAPI, Sigma) for detection and labeled with
ibrant DiO (Molecular Probes) for separation after cocul-
ure with CMCs.
solation of neonatal CMCs. The CMCs were isolated
rom the hearts of neonatal Fisher 344 rats as previously
escribed with minor modifications (15). Briefly, 2- to
-day-old rats were killed, and then hearts were excised.
entricles were minced and trypsinized, and supernatant
as obtained. And then CMCs were separated, placed in
erum-free DMEM for 24 h, and then cultured in 10%
BS-DMEM.
iability assay of MSCs. Viability of MSCs was measured
fter exposure to 0.5% hypoxia for 30 h with trypan blue
xclusion assay.
ifferentiation of MSCs into CMCs: treatment with
Fs and coculture with CMCs. To define optimal treat-
ent condition, we tested differentiation efficacy of BMP-2,
GF-2, IGF-1, and their combination. First, differentiation
fficacy was measured by degree of myocyte enhancer factor
MEF)-2 expression (MEF2-positive cells/total MSCs) on
mmunofluorescent staining with anti-MEF2 (1:200, Santa
ruz Biotechnology, Santa Cruz, California). Treatment of
SCs with a combination of BMP-2, FGF-2, and IGF-1
esulted in the higher percentage of MEF2-positive cells
ompared with BMP-2 or FGF-2 or IGF-1 alone or any
ombination of 2 GFs. Expression of MEF2 reached a peak
t day 7 and then showed a plateau (Online Figs. I and II).
econd, in western blot analysis, expression of CMC-
pecific markers such as Nkx2.5, GATA4, and cTnI was
tronger with combination of BMP-2, FGF-2, and IGF-1
ompared with BMP-2 or FGF-2 or IGF-1 alone or any
ombination of 2 GFs (Online Fig. III). Again, expression
f CMC-specific markers increased until day 7 and then
howed a plateau. On the basis of the results of these
xperiments, differentiation was induced by 7 days’ incuba-
ion with differentiation media (DMEM supplemented
ith 2% FBS, ascorbic acid, and dexamethasone) and after
days’ coculture with CMCs. For GF treatment, FGF-2,
GF-1, and BMP-2 (all from R&D Systems, Minneapolis,
innesota) were added to the differentiation medium. The
oncentration was 50 ng/ml for FGF-2, 2 ng/ml for IGF-1,
nd 10 ng/ml for BMP-2. To evaluate the expression of
ardiac transcription factors and cardiac specific markers,
mmunoblot analysis was performed at 1, 3, 5, and 7 days
fter differentiation induction. After coculture with CMCs,
mmunofluorescence staining was performed to define the
henotype of MSCs with anticardiac troponin I (Santa
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March 4, 2008:933–43 Mesenchymal Stem Cells and Growth Factorsruz Biotechnology) and anticonnexin-43 (Santa Cruz
iotechnology), which were detected with goat antirabbit
gG antibodies (Molecular Probes) conjugated with fluo-
escein isothiocyanate. Meanwhile, in another experiment,
iO-labeled MSCs were separated with fluorescence-
ctivated cell sorter (FACS) from CMCs by detecting DiO
n MSCs. Immunoblot was performed as previously de-
cribed (16). The MSCs were harvested in lysis buffer.
rotein was separated on SDS-polyacrylamide electro-
horesis gel and transferred to a polyvinylidene fluoride
embrane (Millipore, Billerica, Massachusetts). The mem-
rane was blocked and incubated with primary antibodies
gainst GATA-4, NKx-2.5, cardiac troponin-I, connexin-
3, and antialpha tubulin (all from Oncogene, Cambridge,
assachusetts) were used at a dilution of 1:500. As secondary
ntibody, antimouse IgG HRP (Promega, Madison, Wiscon-
in) or antirabbit IgG HRP (Promega) was used at a dilution
f 1:2,500. A chemiluminescent detection reagent ECL (Am-
rsham, Piscataway, New Jersey) was used for detection. To
haracterize the cell type of MSCs after GF treatment and
oculture with CMCs, reverse transcriptase polymerase chain
eaction (RT-PCR) was done as previously described (17).
otal ribonucleic acid (RNA) was isolated by Trizol (In-
itrogen) method and reverse transcribed with reverse tran-
cription system (Clontech, Mountain View, California),
nd complementary deoxyribonucleic acid (cDNA) was
mplified with CMC or myocyte-specific markers
connexin-43, cardiac troponin-I, alpha- and beta-MHC,
lpha-sarcomeric actin, and atrial natriuretic peptide) and
lyceraldehyde 3-phosphate dehydrogenase (GAPDH) by
CR. Primers used were as follows:
Forward primer 5=-TCCTTGGTGTCTCTCGCTTT-3=
and reverse primer 5=-GTTCACCCAATGCGACT-
CTT-3= for connexin-43
Forward primer 5=-CACCCTTCTAAGACCCTCCA-3=
and reverse primer 5=-CCTCCTTCTTCACCTGCT-
TG-3= for cardiac troponin-I
Forward primer 5=-CATAGGGGACCGTAGCAAGA-3=
and reverse primer 5=-CTGCCCCTTGGTGACATA-
CT-3= for alpha-MHC
Forward primer 5=-GCACTGGCCAAGTCAGTGTA-3=
and reverse primer 5=-GGACACGGTCTGAAAGGA-
TG-3= for beta-MHC
Forward primer 5=-GACCACAGCTGAACGTGAGA-3=
and reverse primer 5=-CATAGCACGATGGTCGAT-
TG-3= for alpha-sarcomeric actin
Forward primer 5=-AGGCCATATTGGAGCAAATC-3=
and reverse primer 5=-CCTTAATATGCAGAGTGG-
GAGA-3= for atrial natriuretic peptide
Forward primer 5=-CGTGGAAGGACTCATGAC-3=
and reverse primer 5=-CAAATTCGTTGTCATAC-
CAG-3= for GAPDH pntercellular communication between MSCs and CMCs
hrough gap junction: dye transfer experiment. The
SCs were labeled with DiI, which cannot pass through
he gap junction, and calcein-AM (2.5 mol/l; Calbiochem,
an Diego, California), which can spread only through the
ap junction. And then labeled MSCs were cocultured with
nlabeled CMCs. At 48 h after coculture, dye transfer was
valuated under fluorescence microscope. To selectively
lock gap junctional communication, heptanol (0.5 mmol/
l) was used.
ypoxia exposure to CMCs with or without MSCs
oculture. Hypoxic conditions were created by incubating
MCs at 37°C in airtight chambers with 0.5% oxygen
oncentration under coculture with DiI-labeled MSCs.
fter 24-h hypoxic exposure, cocultured MSCs were elim-
nated by FACS. Then, apoptosis of CMCs was evaluated
y flow cytometry (FACStar plus, Becton Dickinson,
ranklin Lakes, New Jersey) as described previously (18).
he CMCs exposed to hypoxia without coculture were used
s a control. To evaluate the role of gap junction in the
ytoprotective effect of MSCs, heptanol (0.5 mmol/ml) was
dded during hypoxia. To investigate underlying mecha-
ism of cytoprotective effect, the expression of phosphory-
ated Akt and phosphorylated c-AMP response element
inding protein (CREB) in CMCs were evaluated with
mmunoblot analysis.
ssay of IGF-1 and Hepatocyte GF for evaluating
aracrine function of MSCs. After 7 days’ incubation of
SCs in differentiation medium followed by 30 h of
ncubation in conditioned medium (low glucose DMED
ith 10% FBS), IGF-1 and hepatocyte growth factor
HGF) levels in conditioned medium were measured by
nzyme-linked immunosorbent assay (rat IGF-1 enzyme
mmunoassay, Diagnostic Systems Laboratory, Webster,
exas; and rat HGF enzyme immunoassay, Institute of
mmunology, Tokyo, Japan). To exclude the possibility of
ross reaction, antirat IGF-1 antibody that has no reactivity
o human IGF-1 was used for this assay.
at MI model and MSCs transplantation. Rats were
nesthetized with ketamine hydrochloride (100 mg/kg,
uhan Corp., Seoul, Korea) and xylazine (10 mg/kg, Bayer,
hawnee Mission, Kansas) by intraperitoneal injection.
xperimental MI was induced by temporary ligation of the
eft anterior descending artery for 45 min, as previously
escribed (19). Development of MI was confirmed by
chocardiography 7 days after the procedure. Then rats were
andomized into 3 groups: rats receiving control media only
control group), untreated MSCs (untreated MSC group),
nd GF-treated MSCs (treated MSC group). Before trans-
lantation, MSCs were labeled with red DiI for detection at
ater time points. Under anesthesia, each rat received 3
njections (total of 106 cells/heart) into the border zone of
I, approximately 1 to 2 mm apart.
unctional assessment of the infarcted rat heart by
chocardiography. Transthoracic echocardiography was
erformed at just before coronary ligation and 1, 4, and 8
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Mesenchymal Stem Cells and Growth Factors March 4, 2008:933–43eeks after coronary ligation, as described previously (19)
ith an echocardiographic system (Acuson 128-XP system,
cuson, Florida) equipped with a 7-MHz linear–array
ransducer. Left ventricular end-diastolic and end-systolic
imensions (LVEDD and LVESD) were measured ac-
ording to the leading-edge method of the American
ociety of Echocardiography. The LV percent fractional
hortening (%FS) was calculated as 100  (LVEDD 
VESD)/LVEDD.
nduction of arrhythmia. Arrhythmia was induced by
conitine (Sigma) infusion. At 8 weeks after coronary
igation, rats were anesthetized and 24-gauge intravenous
atheter was inserted into the femoral vein for drug admin-
stration. After a 30-min period of stabilization, aconitine
as intravenously infused at a rate of 0.1 ml/min by infusion
ump for 510 s. After aconitine infusion, rats were observed
or 20 min. Electrocardiography (ECG, Surgivet, Wauke-
ha, Wisconsin) was continuously recorded throughout the
xperiment. The incidence of arrhythmias was analyzed in
ccordance with the Lambeth Conventions (20). An ar-
hythmia score was used to indicate the incidence and
uration of arrhythmias, where 0 indicates no arrhythmia; 1:
n arrhythmia duration of 10 s; 2: an arrhythmia duration
f 11 to 30 s; 3: an arrhythmia duration of 91 to 180 s or
Figure 1 Pre-Treatment of MSCs With GFs Augmented the Exp
Specific Genes and Connexin-43 in MSCs, Which Was
(A) Reverse transcriptase-polymerase chain reaction. In the single mesenchymal s
(GFs) does not affect the expression of cardiac specific genes except for the alpha
GFs significantly augmented the induction of cardiac specific genes in MSCs, such
beta myosin heavy chain (MHC) genes. (B) Western blot analysis in the single MS
only in GF-treated MSCs. (C) Western blot analysis after 2 days of coculture with C
in MSC by coculture with CMCs. (D) The percentage of MSCs expressing Cx43 wa
from 5 randomly chosen microscopic fields of 3 separate experiments. (E) Repres
with DAPI (blue). The CMCs were stained with TnI (red) without DAPI. Connexin-43
untreated ones. Connexin-43, which indicates the formation of gap junction (arrow
Arrowheads indicate MSCs expressing both TnI (red) and Cx43. *The MSCs expreeversible ventricular fibrillation (VF) for 10 s; 5: an
rrhythmia duration longer than 180 s or reversible VF for
ore than 10 s; and 6: an irreversible VF or death of the
nimal.
istological analysis of the infarcted rat heart with or
ithout MSCs transplantation. Rats were killed at 8
eeks after coronary ligation for the assessment. Heart
ections embedded in paraffin were cut into 4-m slices,
nd the size of area of fibrosis was determined by image
nalysis system (Image Pro version 4.5; MediaCybernetics,
ethesda, Maryland) on Masson’s trichrome-stained slides.
he measurements of area of fibrosis were performed on 2
eparate sections of each heart, and the averages were used
or statistical analysis. DiI-positive area was measured with
utomated color detection software (Image Pro version 4.5,
ediaCybernetics). For immuno-histochemical analysis,
he rat hearts were cryopreserved in OCT compound
Tissue-Teck, Sakura, Torrance, California). To evaluate
poptosis, the terminal deoxynucleotidyl transferase-
ediated dUTP nick end-labeling (TUNEL) assay
Chemicon S7100 kit, Chemicon, Temecula, California)
nd immunohistochemistry for caspase-3 (Abcam 1:50,
bcam, Cambridge, Massachusetts) were performed. The
UNEL or caspase-3 positive cells were counted in 10
n of Cardiac
ced by Coculture With CMCs
ell (MSC) culture condition, treatment of MSCs with cocktails of growth factors
meric actin. But in coculture condition with cardiomyocytes (CMCs), treatment of
rial natriuretic peptide, connexin-43 (Cx43), cardiac troponin-I (cTnI), alpha and
re condition. The expression of GATA-4 and NKx-2.5 were distinctively induced
The GF treatment augmented the induction of cTnI and Cx43 protein expression
ificantly higher in the GF-treated MSCs than in naïve ones. Data were derived
e images after 2 days of coculture of MSCs with CMCs. The MSCs were labeled
n) was expressed more frequently in the treated MSCs compared with the
s expressed linearly between MSCs and CMCs (TnI positive cells without DAPI).
only Cx43 (magnification 200). T  treated; UT  untreated.ressio
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March 4, 2008:933–43 Mesenchymal Stem Cells and Growth Factorsifferent microscopic fields of at least 3 different sections
rom each animal. Immunofluorescence staining was per-
ormed with anticardiac troponin I (Santa Cruz Biotech-
ology) or anticonnexin-43 (Santa Cruz Biotechnology),
hich was detected with goat antirabbit IgG antibodies
Molecular Probes) conjugated with green fluorescein iso-
hiocyanate. Blue DAPI staining was done to localize the
ucleus. Colocalization of the red DiI-labeled MSCs and
reen connexin-43 or cardiac troponin I expression were
xamined with a confocal microscope (LSM 510 META,
arl Zeiss, Peabody, Massachusetts).
tatistical analysis. All data are presented as mean 
D. Continuous variables were compared by the Student
test, and multiple comparisons were performed by
nalysis of variance with a Bonferroni correction. A value
f p  0.05 was considered significant, and all analyses
ere performed with SPSS version 11.0 (SPSS, Chicago,
llinois).
esults
re-treatment of MSCs with GFs potentiated their
iability in hypoxic condition. The effects of pre-
reatment with GFs combination of FGF-2, IGF-1, and
MP-2 on the viability of MSCs were evaluated. Viability
f MSCs was measured after exposure to 0.5% hypoxia for
0 h. The GF-treated MSCs showed better survival than
ntreated MSCs under hypoxia (viable cell proportion in
Figure 2 Pre-Treatment of MSCs With GFs Enhanced the Forma
(A and B) The MSCs labeled with 1.1=-dioctadecyl-3,3,3=,3=-tetramethylindocarboc
CMCs. Only green calcein-AM is transmittable through functioning gap junction. Ce
MSCs through functioning gap junction. These cells were scarcely observed in the
coculture with GF-treated MSCs (B). (C) After addition of heptanol into coculture c
alone, corroborating that calcein transfer was mediated through gap junction (mag
cation between MSCs and CMCs. Data were derived from 5 randomly chosen micr
as in Figure 1.rypan blue exclusion assay: 67  11% vs. 47  14%, p 
.05).
re-treatment of MSCs with GFs augmented the expres-
ion of various cardiac specific markers and connexin-43,
hich was induced by coculture with CMCs. We evalu-
ted the effects of GF treatment on differentiation of MSCs
nto CMCs. After 7-day treatment with GFs, RT-PCR
howed that expression of alpha-sarcomeric actin was higher
n GF-treated MSCs than untreated MSCs. However, in
he single MSCs culture condition, most of the markers did
ot express irrespective of treatment with GFs. Although
onnexin-43 expressed weakly in both GF-treated MSCs
nd untreated ones, there was no significant difference between
he 2 groups. But, after coculture with CMCs, the messenger
NA (mRNA) expression of CMC- or myocyte-specific
arkers such as atrial natriuretic peptide, troponin-I, alpha
nd beta myosin heavy chain as well as connexin-43 was
ugmented in GF-treated MSCs compared with untreated
nes (Fig. 1A).
Immunoblot analysis showed that treatment with GFs
ncreased the expression of cardiac transcription factors.
he protein expression of GATA-4 and NKx-2.5 were
nduced distinctively during 7 days of culture with GFs
lthough not without GFs (Fig. 1B). After an additional
days of coculture with CMCs, connexin-43 protein was
xpressed, which was enhanced in GF-treated MSCs
ompared with untreated ones (Figs. 1C and 1D). In
mmunofluorescent staining, connexin-43 was expressed
of Functioning Gap Junction With CMCs
perchlorate (DiI) (red) and calcein-AM (green) were cocultured with unlabeled
ing green fluorescence without red denote CMCs that are connected with labeled
ure with untreated MSCs (A), whereas they were frequently observed in the
n with treated MSC and CMCs, there are no CMCs having green fluorescence
ion 200). (D) Treatment with GFs significantly increased intercellular communi-
ic fields of 3 separate experiments. HPF  high power field; other abbreviationstion
yanine
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Mesenchymal Stem Cells and Growth Factors March 4, 2008:933–43inearly between MSCs and CMCs, which suggests the
ormation of gap junction. It was more frequently observed
n the GF-treated MSCs (Fig. 1E). Although western blot
howed that the expression of cardiac troponin I was
ncreased in GF-treated MSCs, the frequency of troponin I
ositive-cells in immunofluorescent staining was not signif-
cantly different between GF-treated and untreated MSCs.
re-treatment of MSCs with GFs enhanced gap junc-
ional communication between MSCs and CMCs. To
valuate gap junctional communication, we examined direct
ye transfer from MSCs to adjacent CMCs. We labeled
SCs both with red DiI and green calcein-AM and
ocultured them with the unlabeled CMCs (Fig. 2). Only
alcein-AM, not DiI, is transmittable through gap junction.
e observed cells stained with green calcein-AM without
ed DiI, which indicated CMCs that have taken up
alcein-AM via functioning gap junctions from MSCs.
uantitative analysis showed that transfer of calcein-AM
rom MSCs to the surrounding CMCs through the gap
unction was more frequent in coculture of CMCs with
F-treated MSCs than with untreated MSCs (Fig. 2D).
fter the addition of a gap junction blocker, calcein-AM
ransfer was blocked (Fig. 2C). This suggested that MSCs
ere linked to CMCs via functioning gap junctions. There-
ore, pre-treatment with GFs enhanced not only the expres-
ion of connexin-43 in MSCs but also the gap junctional
ommunication with CMCs.
Figure 3 Pre-Treatment of MSCs With GFs Potentiated
Their Cytoprotective Effects on CMCs, Which Was Me
(A to D) Fluorescence-activated cell sorter (FACS) for evaluating apoptosis. The CM
MSCs (B), and GF-treated MSCs (C). Hypoxia-induced apoptosis of CMCs was red
treated MSCs. Heptanol partially inhibited cytoprotective effects of GF-treated MSC
phospho-c-AMP response element binding protein (p-CREB) increased in CMCs coc
blocker. (F) Enzyme-linked immunosorbent assay (ELISA) for insulin-like GF (IGF)-1
HGF between untreated and GF-treated MSCs. Abbreviations as in Figure 1.F-treated MSCs protect CMCs through a gap
unction-mediated mechanism. We investigated whether
Fs potentiated the cytoprotective effect of MSCs and
hether this effect is mediated through the gap junction
Fig. 3). After 24 h of hypoxia, the apoptotic fraction of
MCs was significantly reduced in coculture condition
ith MSCs compared with CMCs single culture (Figs.
A and 3B). Such antiapoptotic action of MSCs on
MCs was significantly potentiated in the coculture with
F-treated MSCs (Fig. 3C). Treatment of heptanol
artially inhibited antiapoptotic effects of treated MSCs
n CMCs (Fig. 3D). These data suggest that MSCs exert
protective effect on CMCs via gap junctions, which is
ugmented by GF treatment of MSCs. Additionally,
xpression of phospho-Akt and phospho-CREB in-
reased in CMCs cocultured with GF-treated MSCs
ompared with untreated MSCs, which was also reversed
y heptanol (Fig. 3E). However, there was no significant
ifference in the capacity to secrete IGF-1 or HGF
etween untreated and treated MSCs (Fig. 3F). Collec-
ively, these results suggest that, at least partially, cyto-
rotective effect of MSCs was mediated through gap
unction and that GF pre-treatment of MSCs potentiated
he gap junction-mediated cytoprotective effect of MSCs.
he increase of intercellular communication through gap
unction activated Akt and CREB pathway in CMCs.
d Through Gap Junction
ere exposed to hypoxia alone as a control (A), under coculture with untreated
y coculture with MSCs, which was more notable in coculture condition with GF-
MCs (D). (E) Western blot analysis. The expression of phospho-Akt (p-Akt) and
with GF-treated MSCs under hypoxia, which was reversed by gap junctional
epatocyte GF (HGF). There was no significant difference in secretion of IGF-1 anddiate
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March 4, 2008:933–43 Mesenchymal Stem Cells and Growth Factorsransplantation of GF–pre-treated MSCs showed a su-
erior myocardial salvage of rat infarcted heart to that of
aïve ones. The area of fibrotic scar in the infarcted rat
eart was significantly smaller when GF-treated MSCs
ere transplanted than when untreated MSCs were at 8
eeks after MI (Figs. 4A and 4B). Left ventricular %FS,
VESD, and LVEDD were similar among all 3 groups at
aseline. At 8 weeks, the motion of the LV anterior wall was
bviously better when transplanted with the GF-treated
SCs than with the untreated MSCs or with control media
Fig. 4C). Although LVEDD was not significantly different
mong 3 groups (Fig. 4D), %FS were significantly higher
hen transplanted with the GF-treated MSCs than with
he untreated MSCs or with control media at 4 and 8 weeks
fter MI (Fig. 4E).
re-treatment of MSCs with GFs enhanced engraftment
f MSCs and gap junction formation with CMCs and
educed apoptosis in infarcted myocardium. Trans-
lanted MSCs were detected until 8 weeks after MI in the
nfarct border zone. At 2 and 8 weeks, the proportion of
SCs expressing connexin-43 was higher in the heart
ransplanted with GF–pre-treated MSC than with un-
reated ones. The gap junction formation was more fre-
Figure 4 Transplantation of GF–Pre-Treated MSCs Showed a Gr
Myocardial Salvage in Rat Infarcted Heart Than That
(A) Representative images of infarcted rat heart. Heart obtained 8 weeks after my
than that with transplantation of untreated MSCs (Masson’s trichrome staining: bl
the infarcted heart transplanted with GF-treated MSCs compared with that with un
finding. The anterior wall motion was preserved better in the GF-treated MSC group
shortening (%FS) was higher in the group transplanted with GF-treated MSC than w
dimension (LVEDD) was significantly smaller in groups with MSC transplantation th
with media injection (n  8), MI with transplantation of untreated MSC (n  10), a
0.05 versus untreated MSC group. Abbreviations as in Figure 1.uently observed between MSCs themselves or MSCs and
urrounding CMCs in the GF-treated MSC group com-
ared with the untreated MSC group (Figs. 5A to 5C). In
ddition to quantitative increase in the expression of
onnexin-43, expression pattern was more organized in the
eart transplanted with GF–pre-treated MSC than with
ntreated ones (Online Fig. IV). However, the expression of
roponin-I in MSC was similar in the treated MSC group
nd untreated ones (Online Fig. V). Area of surviving
SCs was significantly greater in the GF-treated MSC
roup compared with the untreated group at 2 weeks (Figs.
D and 5E). Apoptosis was significantly reduced in the
nfarcted heart when transplanted with the GF-treated
SCs than with the untreated ones at 2 weeks after MI (1
eek after MSC implantation) (Figs. 5F to 5H). Taken
ogether, pre-treatment of MSCs with GFs enhances gap
unction formation and cell survival in the infarcted heart.
ransplantation of GF–pre-treated MSCs did not aggra-
ate susceptibility to drug-induced arrhythmia after
I. The arrhythmia induction experiment was performed
n 20 rats (10 rats transplanted with the GF-treated MSCs
nd with untreated MSCs, respectively) at 8 weeks after MI.
uring and after aconitine infusion, we were able to observe
r
treated MSCs
al infarction (MI), and transplantation of GF-treated MSC showed smaller infarct
icates infarcted scar tissue). (B) The area of fibrosis was significantly smaller in
MSCs (n  7 in each group). (C) Representative figures of echocardiographic
nd E) Although there was no significant difference at baseline, percent fractional
treated MSC or with media at 8 weeks after MI. Left ventricular end-diastolic
h media at 4 weeks, but there was no significant difference at 8 weeks. The MI
with GF-treated MSC (n  9). *p  0.05 versus media injection group; #p eate
of Un
ocardi
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Mesenchymal Stem Cells and Growth Factors March 4, 2008:933–43remature ventricular contraction (PVC), ventricular tachy-
ardia, and VF (Fig. 6A). There were 5 rats in the
F-treated MSC group and 8 in the untreated MSC group
howing any kind of arrhythmia. Ventricular tachycardia
as induced in 2 in the GF-treated MSC group and 3 in the
ntreated group. One rat in each group died, owing to
rreversible VF. Rats transplanted with the treated MSCs
ad a tendency toward a lower arrhythmia score and less
requent PVCs, which did not reach statistical significance
Figs. 6B and 6C). These data suggest that enhanced
xpression of connexin-43 in MSCs and gap junctional
ommunication with CMCs by GF pre-treatment of MSCs
t least did not aggravate arrhythmia after transplantation of
SCs to the infarcted myocardium.
iscussion
n this study, we showed that pre-treatment of MSCs with
combination of GFs (FGF-2  IGF-1  BMP-2)
nhanced the expression of cardiac transcription factors and
Figure 5 Treatment of MSCs With GFs Enhanced Their Engraftm
Junction Formation With CMCs and Reduced Apoptos
(A and B) Representative figures of immunostaining at 2 and 8 weeks after MI. Tr
nuclei, were engrafted in the myocardium (unlabeled CMCs with DAPI nuclear stain
heart transplanted with the GF–pre-treated MSCs than with the untreated MSCs. C
CMCs (arrowheads). (C) The percentage of MSCs expressing connexin-43 was sig
positive area, which might reflect the engraftment area of transplanted MSCs, was
untreated ones at 2 weeks after MI. The statistical significance was lost at 8 wee
in the infarcted myocardium transplanted with GF–pre-treated MSCs than with naïv
(TUNEL) staining. (G) Immunohistochemistry for caspase-3. At 2 weeks after MI, a
pretreated MSCs than with untreated ones. (H) Three randomly selected fields in
ures 1, 2, and 5.hat these primed MSCs, compared with naïve MSCs, khowed the augmented induction of cardiac specific genes
y coculture with CMCs. With the greater expression of
onnexin-43 and gap junction formation between CMCs,
he primed MSCs showed better cytoprotective effects on
MCs than naïve ones. Furthermore, the cytoprotective
ffect on CMCs was mediated through gap junctions, which
s a novel mechanism to explain the therapeutic effect of
SCs. In rat MI model, transplantation of GF–pre-treated
SCs after MI enhanced gap junction formation and cell
urvival in the infarcted myocardium and reduced infarct
ize, leading to the improved LV function.
F treatment and cardiomyogenic differentiation of
SCs. Bone morphogenetic protein, a member of the
ransforming growth factor (TGF) family, and FGF have
een reported to play important roles in induction of cardiac
ranscription factors in developing embryos (21) and to
nduce cardiomyogenic differentiation from noncardiac me-
odermal cells (11,22). The BMP-2 in vivo induced expres-
ion of cardiac-specific transcription factors (8,11) and is
and Gap
the Infarcted Myocardium
nted MSCs, labeled with DiI (red) before injection and with DAPI (blue) at
ly). There was significantly higher connexin-43 expression in the infarcted
in-43 (green) was expressed between MSCs (arrows) or between MSCs and
tly higher in the GF–pre-treated MSCs than in the untreated ones. (D) DiI-
cantly greater in the heart transplanted with GF–pre-treated MSCs than with the
Low-power views, which showed that DiI-positive area at 2 weeks was greater
. (F) Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling
is (arrows) was significantly lower in the infarcted heart transplanted with GF-
rate slides/animal (n  5 in each group) were counted. Abbreviations as in Fig-ent
is in
anspla
ing on
onnex
nifican
signifi
ks. (E)
e ones
poptos
2 sepanown to play an important role in the process of heart
d
t
c
e
e
o
p
t
e
e
d
c
t
g
t
a
c
m
t
C
g
v
h
s
j
t
r
i
s
c
n
r
i
c
i
d
T
c
G
G
C
w
p
a
s
M
a
f
C
M
t
G
p
t
m
t
t
d
t
c
p
t
m
f
m
s
o
g
d
m
M
t
w
a
i
941JACC Vol. 51, No. 9, 2008 Hahn et al.
March 4, 2008:933–43 Mesenchymal Stem Cells and Growth Factorsevelopment (23,24). The FGF-2 also plays a pivotal role in
he differentiation process of resident cardiac progenitor
ells into functional CMCs (10). The IGF-1 was shown to
nhance cellular engraftment and host organ-specific differ-
ntiation of embryonic stem cells after injection in the area
f acute myocardial injury (9) and to enhance survival and
roliferation of cardiac stem cells (25).
In the present study, we demonstrated that a combined
reatment with FGF-1, IGF-1, and BMP-2 increased the
xpression of cardiac transcription factors in MSCs. The
xpression of CMC-specific genes, however, was not in-
uced by treatment with GFs in the MSCs single culture
ondition. But in coculture condition with CMCs, GF-
reated MSCs showed a greater expression of cardiac specific
enes including connexin-43 and a better gap junction forma-
ion with CMCs than naïve MSCs. We think that MSCs
fter treatment with GFs are “primed” MSCs expressing
ardiac transcription factors or “committed” MSCs into
yocyte lineage but not mature or immature CMCs. But
hese “primed” MSCs have a capability to differentiate to
MC-like cells in coculture with CMCs in vitro, to form
ap junction, and to survive in the infarcted myocardium in
Figure 6 Pre-Treatment of MSCs With GFs Did Not Aggravate
Arrhythmogenecity of Transplanted MSCs
(A) Representative figures of electrocardiographic recording in rats. (B) The
arrhythmia score according to Lambeth Convention showed a tendency to
be lower in the infarcted heart transplanted with GF–pre-treated MSCs than in
the heart with the untreated MSCs (1.1  0.6 vs. 2.4  0.7, p  0.09).
(C) The difference of premature ventricular complex counts between the GF-
treated MSC and the untreated group did not reach statistical significance
(402  288 vs. 753  305, p  0.11). PVC  premature ventricular contrac-
tion.; other abbreviations as in Figure 1.ivo more than naïve MSCs. Our data suggested that GFs jave the potential to induce MSCs to express CMC-
pecific genes and connexin-43 and to form functioning gap
unction, in response to appropriate stimuli such as cocul-
ure with CMCs. Although the underlying mechanism
esponsible for increased expression of connexin-43 by GFs
n MSCs remains unclear, FGF-2 and IGF-1 have been
hown to increase connexin-43 expression and intercellular
ommunication (12,13).
Our data suggest that contact with CMCs would be
eeded to differentiate MSCs into CMC lineage. It was
eported that differentiation of bone marrow stromal cells
nto cells with cardiac phenotype requires intercellular
ommunication with myocytes (26). However, whether
ntercellular communication is essential for cardiomyogenic
ifferentiation is unknown. Li et al. (27) reported that
GF-beta induced the myogenic differentiation of stem
ells without coculture.
ap junction and cytoprotective effect. In this study,
F–pre-treated MSCs exerted better protective effects on
MCs than untreated MSCs, and these protective effects
ere mediated through gap junctions. Currently, the cyto-
rotective effect of MSCs is regarded as one of the mech-
nisms to explain the therapeutic effects of MSCs. Previous
tudies have focused on paracrine effects of MSCs. The
SCs secrete large amounts of various angiogenic and
nti-apoptotic factors (6), and the conditioned medium
rom cultured MSCs were shown to reduce apoptosis of
MCs exposed to hypoxia (5). We also observed that
SCs secreted IGF-1 and HGF in this study. However,
he capacity to secrete cytokines is not different between
F-treated and untreated MSCs in this study. Therefore,
aracrine effects can not explain the difference in cytopro-
ective effects between GF-treated and untreated MSCs.
In this study, formation of functional gap junctions was
ore efficient in GF-treated MSCs compared with un-
reated MSCs, and the blockade of gap junctions reversed
he protective effects of MSCs on CMCs and abolished the
ifference in protective effects on CMCs between GF-
reated and untreated MSCs. These data suggest that the
ytoprotective effects of MSCs are mediated not only by
aracrine actions but also by direct cell-to-cell communica-
ion through gap junctions and that treatment with GFs
ight potentiate gap junction-mediated cytoprotective ef-
ect. Recent data support the hypothesis that gap junction
ight propagate cell survival and death signals (28). In our
tudy, connexin-43 expression that indicated the formation
f gap junction was more prominent in GF-treated MSC
roup in vitro and vivo. And dye transfer experiments
emonstrated that metabolic coupling with CMCs was
ore efficient in GF-treated MSCs than in untreated
SCs. Although we could not confirm which material was
ransferred from MSCs to CMCs, second messengers,
hich have been known to pass through the gap junction,
re potential candidates. Cyclic adenosine monophosphate
s a well-known second messenger that can pass through gap
unction (7) and phosphorylate CREB, which in turn exerts
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Mesenchymal Stem Cells and Growth Factors March 4, 2008:933–43n antiapoptotic effect (29). In the present study, we showed
ncreased phosphorylation of CREB in CMCs cocultured
ith treated MSCs. Moreover, the Akt pathway was acti-
ated in CMCs cocultured with treated MSCs. Enhanced
xpression of CREB and Akt in CMCs cocultured with
F-treated MSCs were inhibited by blocking gap junction.
n short, MSCs have a cytoprotective effect on CMCs
hrough the gap junction, which is potentiated by treatment of
SCs with GFs that facilitate the expression of connexin-43
nd formation of functional gap junctions.
educed infarct size and improved systolic function by
ransplantation of GF–pre-treated MSCs. There are sev-
ral possible mechanisms that could explain the difference
etween GF-treated MSCs and untreated ones in reduction
f infarct size and preservation of LV systolic function.
irst, GF treatment might make MSCs stronger against
poptosis. The GF–pre-treated MSCs showed better sur-
ival against hypoxia. The DiI-positive area was greater in
he infarcted myocardium transplanted with GF–pre-
reated MSCs than with naïve MSCs in the early post-
ransplantation period. Surviving MSC can contribute to
ardiac repair through direct differentiation and paracrine
nd cytoprotective action. Thus the more MSCs survive, the
igger improvement of cardiac function can be expected
30). Anti-apoptotic effects of GF treatment on MSCs can
e explained by at least 2 mechanisms: 1) FGF-2 prolonged
elomerase length and life span of MSCs and is useful in
btaining a large number of cells with preserved differenti-
tion potential (31); and 2) FGF and IGF-1 activate
I3-kinase/Akt pathway, which is known to mediate anti-
poptotic signaling (32,33). However, the survival benefit of
SCs was attenuated at 8 weeks, and absolute amounts of
urviving MSCs were also markedly decreased. Thus, this
echanism can not solely explain the beneficial effects of
F treatment observed at 8 weeks. Second, as discussed
reviously, GF treatment enhanced gap junction-mediated
ytoprotective effect of MSCs on CMCs. Finally, the better
V systolic function in the treated MSC group might be
ue to synchronized contraction. Enhanced intercellular
ommunication through gap junction might lead to electri-
al synchronization and then synchronous contraction
34,35). Therefore, better-coordinated LV systolic contrac-
ion can be expected when GF–pre-treated MSCs are
ransplanted.
ffects of MSC transplantation on arrhythmogenecity of
nfarcted myocardium. Since proarrhythmic effects of
keletal myoblasts have been reported, there have been
oncerns about proarrhythmic potential of stem cell trans-
lantation. Mixtures of MSCs and neonatal rat ventricular
yocytes can produce an arrhythmogenic substrate (36).
hether increased gap junctional communication is favor-
ble remains uncertain. However, increased expression of
onnexin-43 has been reported to reduce inducible arrhyth-
ia in infarcted heart (37). Concordant with the previous
tudy, transplantation of GF–pre-treated MSCs, which can
ake higher expression of connexin-43 and functional gapunctions, did not aggravate arrhythmic risk after MI in our
tudy.
tudy limitations. There are several limitations to this
tudy. First, we used human GFs for pre-treatment of
SCs isolated from rat bone marrow. However, structural
omology of these GFs is very high between humans and
ats (38,39). Second, because we treated MSCs with a
ombination of 3 GFs, the effect of individual GF and the
nderlying mechanism of individual effect were not under-
tood. Third, DiI is a membrane dye and might have
imitation for detection of transplanted MSCs 8 weeks later.
owever, Dai et al. (40) reported that the DiI-positive cells
ere observed at 3 and 6 months after transplantation of
iI-labeled MSCs into the scar of a 1-week-old infarcted
yocardium. And DiI diffuses within the plasma mem-
rane, resulting in staining of the entire cell, which was
bserved in our study as well as a previous one (40).
onclusions
e found that the priming of MSCs with a combination of
GF-2, IGF-1, and BMP-2 enhanced commitment of
SCs to CMC lineage in the coculture with CMCs. These
F-primed MSCs with better expression of connexin-43
howed a greater cytoprotective effect on CMCs, which was
ediated through gap junction. Moreover, coupling
hrough gap junction might explain the improvement of LV
ystolic function after transplantation of primed MSCs to
he infarcted myocardium compared with naïve MSCs.
reatment of MSCs with GFs might be a physiological and
easible strategy to increase therapeutic efficacy of MSC
ransplantation to the infarcted myocardium, which has a
ignificant clinical impact.
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